Rice Hall James & Associates LLC Sells 12,456 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Rice Hall James & Associates LLC cut its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 2.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 515,889 shares of the specialty pharmaceutical company's stock after selling 12,456 shares during the quarter. Supernus Pharmaceuticals makes up approximately 1.0% of Rice Hall James & Associates LLC's portfolio, making the stock its 29th largest holding. Rice Hall James & Associates LLC owned 0.92% of Supernus Pharmaceuticals worth $16,895,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in SUPN. Raiffeisen Bank International AG purchased a new stake in Supernus Pharmaceuticals during the fourth quarter valued at about $25,000. Financial Management Professionals Inc. purchased a new stake in Supernus Pharmaceuticals during the first quarter valued at about $30,000. Versant Capital Management Inc lifted its holdings in Supernus Pharmaceuticals by 6,931.3% during the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock valued at $37,000 after purchasing an additional 1,109 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in Supernus Pharmaceuticals during the fourth quarter valued at about $42,000. Finally, Mark Sheptoff Financial Planning LLC purchased a new stake in Supernus Pharmaceuticals during the fourth quarter valued at about $52,000.

Supernus Pharmaceuticals Trading Up 0.2%

Shares of Supernus Pharmaceuticals stock traded up $0.07 on Thursday, reaching $33.59. The stock had a trading volume of 945,860 shares, compared to its average volume of 494,198. Supernus Pharmaceuticals, Inc. has a 1 year low of $27.05 and a 1 year high of $40.28. The company has a market cap of $1.88 billion, a P/E ratio of 30.26 and a beta of 0.70. The business's 50 day moving average is $32.40 and its two-hundred day moving average is $33.68.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, July 12th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.